Secondary analysis evaluates effect of Women’s Health Initiative dietary intervention.

Guest Post by David Kliff, Editor, Diabetic Investor
Senseonics has taken their Eversense implantable CGM before an FDA panel, and Bigfoot has announced they have closed their series B $55 million financing round. The FDA has approved Dexcom’s G6 system, pushing shares in the company higher in early trading. And while they didn’t announce anything recently, our friends at Tandem are feeling the love as shares continue to surge higher in anticipation of their new system, which has low glucose suspend.

Mr. Hernandez's labs are notable for A1C 7.5, FPG 137 mg/dL, LDL-cholesterol 190 mg/dL, HDL-cholesterol 38 mg/dL, and triglycerides 232 mg/dL. You discuss his lab results, his diagnosis, and how to manage diabetes, then you make referrals to the appropriate diabetes team clinicians. You start Mr. Hernandez on metformin, lifestyle modifications, an ACE inhibitor, and a statin. What clinical parameters are you looking to achieve? A. A1C less than 7%, BP less than 130/80 mmHg, LDL less than 100 mg/dL B. A1C less than 7%, BP less than 130/90 mmHg, LDL less than 100 mg/dL C. A1C less than 7%, BP less than 140/80 mmHg, LDL less than 100 mg/dL D. A1C less than 7%, BP less than 140/90 mmHg, LDL less than 150 mg/dL Follow the link for the answer.

Do you prescribe sulfonylureas?

In this week's Homerun Slides, understanding the relationship between diabetes and hypertension.

What is insulin resistance? Broadly, insulin resistance can be defined as an abnormal biologic response to insulin; insulin, whether endogenous or exogenous in origin, has limited ability to reverse a hyperglycemic metabolic state.Thus a person with insulin resistance is, almost inevitably, progressing towards developing frank type 2 diabetes (T2DM) if an intervention (usually lifestyle) is not implemented. Due to the very close link between diabetes and insulin resistance, no formal clinical definition of insulin resistance has emerged.We will discuss the potential clinical use of the insulin resistance syndrome and the metabolic syndrome later in the chapter. For now, we focus on investigation of insulin resistance as a useful entity for research concepts, and in particular discuss its biologic consequences by describing its associated risk factor perturbations.

Additional conditions more likely in those diagnosed later in life.

Canagliflozin is found to have reduced risk of cardiovascular death or hospitalization due to heart failure in type 2 diabetes patients.

Use of high temperature, open flame for cooking both red meat and chicken associated with increased risk.

Study shows greater than 20% weight decrease, especially in men, can significantly increase risk of fragility fractures.